Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $239,742.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $84.12, for a total transaction of $239,742.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at $14,934,917.16. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 3.6%

Shares of ANIP opened at $86.03 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50. The firm has a market cap of $1.96 billion, a P/E ratio of 21.78 and a beta of 0.43. The firm’s 50-day simple moving average is $80.89 and its 200 day simple moving average is $79.39. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period last year, the business posted $1.70 earnings per share. The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently made changes to their positions in the company. Divisadero Street Capital Management LP bought a new stake in ANI Pharmaceuticals during the third quarter worth $21,454,000. Apis Capital Advisors LLC boosted its holdings in shares of ANI Pharmaceuticals by 28.1% in the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after purchasing an additional 36,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the last quarter. Oliver Luxxe Assets LLC bought a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $1,823,000. Finally, Penn Capital Management Company LLC raised its holdings in shares of ANI Pharmaceuticals by 2,058.9% during the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after buying an additional 131,030 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.